Navigation Links
Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents

nts With Attention-Deficit/Hyperactivity Disorder (Trial 303)

J. Biederman, M.D.; R. Melmed, M.D.; Anir Patel, M.D.; Keith McBurnett, M.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.

APA Poster # NR657

Wednesday, May 23, 2007 at 12 p.m. PDT (3 p.m. EDT)

Interim Results of a Long-Term, Open-Label Study of Guanfacine Extended Release in Children and Adolescents Aged 6 to 17 Years With Attention- Deficit/Hyperactivity Disorder (Trial 305)

F. Sallee, M.D.; J. Biederman, M.D.; J. McGough, M.D.; T. Wigal, Ph.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on ADHD, human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company's website: www.shire.com

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties inclu
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/20/2014)...   Ventana Medical Systems, Inc.  (Ventana), a ... its VENTANA System for Primary Diagnosis 1 ... for routine pathology, including primary diagnosis with human ... software coupled with either the VENTANA iScan Coreo ... automated digital slide creation, case management and computer ...
(Date:8/20/2014)... LAKE CITY , Aug. 20, 2014 ... revolutionary mobile diagnostic platform during a special event at ... Utah , on September 5, 2014. The event, ... LiveStreamed on the ApolloDx website, www.apollodx.com .    ... transform diagnostic testing," said Jared Bauer , Co-Founder ...
(Date:8/20/2014)... , Aug. 20, 2014 Trovagene, Inc. ... announced today that results from two clinical studies will ... for the Company,s urine-based diagnostic test for the detection ... IPV conference is scheduled to take place in ... to 25 th . Additionally, a new U.S. patent ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
... HeartWare International, Inc. (NASDAQ: HTWR ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Godshall is scheduled to present at the Lazard Capital ... p.m. ET on Thursday, September 22, 2011.  The one-day ...
... and SEATTLE, Sept. 19, 2011 Varian ... Calypso Medical Technologies, Inc., today announced they have signed ... a privately-owned, Seattle-based developer and supplier of specialized products ... during radiosurgery and radiotherapy.  The acquisition, which is anticipated ...
Cached Medicine Technology:HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day 2Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 2Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 3Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 4Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 5
(Date:8/20/2014)... Missouri federal judge has remanded a lawsuit filed by a ... NaturaLyte to the City of St. Louis Circuit Court, reports ... rejected an assertion by the defendants that the plaintiffs’ claims ... v. Fresenius Medical Care North America Inc., et al., No. ... of the dialysis products GranuFlo and NaturaLyte. In 2012, the ...
(Date:8/20/2014)... News) -- Leaving the car at home and getting to ... your health, a new study indicates. Researchers looked at ... 76 percent of men and 72 percent of women drove ... women used public transit, and 14 percent of men and ... drove to work weighed more and had higher levels of ...
(Date:8/20/2014)... The Workgroup for Electronic Data Interchange ... use of health IT to create efficiencies in ... its annual fall conference, WEDI-Con 2014: The Next ... take place at the HYATT Regency in Reston, ... cross-section of payers, providers, government regulators, industry vendors ...
(Date:8/20/2014)... WI (PRWEB) August 20, 2014 Parents ... While the transition from summer months means buying textbooks ... element that is often a forgotten part of the ... , According to the American Psychological Association, 27% of ... year. Nearly half (45%) say they are stressed by ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Verndale is ... Inc. 500|5000 list; an exclusive list ranking the fastest-growing ... are ranked according to their yearly percentage revenue growth ... 8th time on the Inc. 5000 list where it ... Company, Verndale offers its clients a wide range of ...
Breaking Medicine News(10 mins):Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Want to Stay Slim? Leave the Car at Home 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2
... Simple exercise routines can improve lung function and overall fitness ... a small new study suggest. Cystic fibrosis, or CF, ... mucus in the lungs, resulting in frequent lung infections, breathing ... regimens are difficult to adhere to long-term, so a team ...
... at The Scripps Research Institute have found a temperature-sensing protein within ... activate an immune response. This process can occur as temperature rises, ... immune cells are "called" from the body,s warm interior to a ... online ahead of print by Nature Chemical Biology , is ...
... FRIDAY, May 6 (HealthDay News) -- Nail salon workers may ... a new study warns. Researchers recruited 80 Vietnamese women ... their work-related exposure to toluene, ethyl acetate and isopropyl acetate. ... Journal of Public Health , showed that the workers were ...
... bacteria associated with exposure to livestock was recently discovered ... contact with livestock, according to University of Iowa researchers. ... study of Staphylococcus aureus in child day care facilities ... in the UI College of Public Health, for her ...
... Reinberg HealthDay Reporter , THURSDAY, May ... antibiotics can often cure appendicitis, surgery remains the ... appendicitis may be treated with antibiotics alone, but ... surgery, and it is difficult to discern between ...
... May 6 (HealthDay News) -- Americans walked and biked a ... new research finds. But the increases were minor, especially ... in the American Journal of Public Health . ... 2009 U.S. National Household Travel Surveys and found that the ...
Cached Medicine News:Health News:Everyday Exercise Can Help Kids With Cystic Fibrosis: Study 2Health News:Scripps Research scientists show how shifts in temperature prime immune response 2Health News:Scripps Research scientists show how shifts in temperature prime immune response 3Health News:Study finds livestock-related 'Staph' strain in child care worker 2Health News:Surgery May Beat Antibiotics for Appendicitis, Study Finds 2Health News:Surgery May Beat Antibiotics for Appendicitis, Study Finds 3Health News:Americans Walking, Biking a Bit More, Research Shows 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: